Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celcuity Inc.CELC · Entity 3991 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celcuity Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,745 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 1,530 · Balance 1,745 F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 1,747 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2020 Filed Nov 4, 2020 20:23 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 799 | $172.50 | $137,827.50 |
DisclosureSEC source: 0001203311-20-000118 · edgardoc.xml · nonDerivative · entry 6 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,941 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 20:23 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 799 | $18.46 | $14,749.54 |
DisclosureSEC source: 0001203311-20-000118 · edgardoc.xml · nonDerivative · entry 5 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 20:23 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,620 | $172.50 | $279,450.00 |
DisclosureSEC source: 0001203311-20-000118 · edgardoc.xml · nonDerivative · entry 4 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,941 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 20:23 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 1,620 | $26.10 | $42,282.00 |
DisclosureSEC source: 0001203311-20-000118 · edgardoc.xml · nonDerivative · entry 3 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:23 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 7,468 | $166.00 | $1,239,691.73 |
DisclosureSEC source: 0001203311-20-000118 · edgardoc.xml · nonDerivative · entry 2 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,941 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $166.00 to $166.02. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:23 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,533 | $167.80 | $928,437.40 |
DisclosureSEC source: 0001203311-20-000118 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,409 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 19:25 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 555 | $155.69 | $86,410.28 |
DisclosureSEC source: 0001203311-20-000101 · edgardoc.xml · nonDerivative · entry 2 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,942 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 19:25 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 578 | $155.69 | $89,991.25 |
DisclosureSEC source: 0001203311-20-000101 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,497 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 18:26 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,027 | $158.17 | $636,941.33 |
DisclosureSEC source: 0001203311-20-000086 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,075 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:32 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 18,711 | $0.00 Strike: $161.82 | $0.00 |
DisclosureSEC source: 0000899243-20-022639 · doc4.xml · derivative · entry 3 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,711 Underlying: Common Stock · 18,711 shares Expires 2030-08-17 F4 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:32 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 617 | $0.00 Strike: $161.82 | $0.00 |
DisclosureSEC source: 0000899243-20-022639 · doc4.xml · derivative · entry 2 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617 Underlying: Common Stock · 617 shares Expires 2030-08-17 F4 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:32 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 7,795 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022639 · doc4.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,102 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of August 15, 2020 until all shares are fully vested at the end of four years. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 18:34 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 712 | $167.49 | $119,252.88 |
DisclosureSEC source: 0001203311-20-000062 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,307 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 15, 2020 Filed May 19, 2020 18:47 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 3,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-20-000038 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,019 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the vesting commencement date of May 15, 2020 until all shares are fully vested four years from the vesting commencement date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:54 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,942 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-20-000036 · edgardoc.xml · derivative · entry 3 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,942 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options were fully vested on 08/24/2015. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:54 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 6,942 | $166.00 | $1,152,372.00 |
DisclosureSEC source: 0001203311-20-000036 · edgardoc.xml · nonDerivative · entry 2 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,575 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:54 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 6,942 | $15.46 | $107,323.32 |
DisclosureSEC source: 0001203311-20-000036 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 08, 2020 Filed May 8, 2020 19:54 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,942 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-20-000032 · edgardoc.xml · derivative · entry 3 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,942 Underlying: Common Stock · 6,942 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 12/24/14. Read SEC document |
| May 08, 2020 Filed May 8, 2020 19:54 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 6,942 | $163.02 | $1,131,667.49 |
DisclosureSEC source: 0001203311-20-000032 · edgardoc.xml · nonDerivative · entry 2 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,575 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $163.00 to $163.48. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 08, 2020 Filed May 8, 2020 19:54 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 6,942 | $15.46 | $107,323.32 |
DisclosureSEC source: 0001203311-20-000032 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 2,000 | $166.11 | $332,220.20 |
DisclosureSEC source: 0001203311-20-000026 · edgardoc.xml · nonDerivative · entry 2 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,575 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,056 | $166.23 | $508,006.21 |
DisclosureSEC source: 0001203311-20-000026 · edgardoc.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,575 Read SEC document |
| April 19, 2020 Filed Apr 22, 2020 06:12 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 822 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011133 · doc4.xml · nonDerivative · entry 3 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,631 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F4 · shares: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 4/19/2022, subject to continuous service with the Company until the vesting date. F5 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 19, 2020 Filed Apr 22, 2020 06:12 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 326 | $139.91 | $45,612.19 |
DisclosureSEC source: 0000899243-20-011133 · doc4.xml · nonDerivative · entry 2 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,809 F3 · shares: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| April 19, 2020 Filed Apr 22, 2020 06:12 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,364 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011133 · doc4.xml · nonDerivative · entry 1 ROMP CHARLES R · CIK 0001809717 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,135 F2 · shares: The performance criteria for these restricted stock units were met. These restricted stock units became fully vested on 4/19/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.